Discover 2,729 paid clinical trials in Ontario. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Filter
1
Filter results
Results: 2,729
Active & Responsive
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Rimouski, Boston MA, New Haven CT, Quebec,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Quebec, Chicoutimi, Mineola NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06841354
Phase3, Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Waterford CT, Guilford CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
Biofeedback Training for Hemianopia
for
Hemianopia, Brain Injuries
Location: Toronto
Sponsor: University Health Network, Toronto
Sex: All
Age: 18 - 70+
Code: NCT06995313
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
for
Generalized Myasthenia Gravis
Location: Boston MA, Quebec, Washington D.C. DC, Ottawa,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06744920
Phase3, Recruiting
Active & Responsive
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation